Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NIfCT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XkRmlEPTB;MD6wNlgxPiEQvF2= NW\UU5dHW0GQR1XS
KS-1 M{nYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEO4N|Uh|ryP NH;QZWJUSU6JRWK=
TE-11 MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPBTWM2OD1yLkC3PFIzKM7:TR?= NVz2TXVtW0GQR1XS
EW-1 NH\ROVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEi1PFUh|ryP M1zDc3NCVkeHUh?=
HMV-II MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPpN2pKSzVyPUCuNFg5PDZizszN NFP2bnpUSU6JRWK=
COLO-205 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLIO3IyUUN3ME2wMlExPDV2IN88US=> NILXbFVUSU6JRWK=
ES1 NY\DbGVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjnTWM2OD1yLkGwOlk3KM7:TR?= MnfIV2FPT0WU
GDM-1 NV64e25ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu1TXF1UUN3ME2wMlE{Pjd{IN88US=> NH;sXJhUSU6JRWK=
ML-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrHfoxKUUN3ME2wMlE2QDl4IN88US=> NHP5WG9USU6JRWK=
Saos-2 M1XqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;ibmpKSzVyPUCuNVY2OjZizszN MmTiV2FPT0WU
NCI-H1355 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\RTWM2OD1yLkG4NVM2KM7:TR?= NYDGelczW0GQR1XS
G-401 M3vVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnaWJZKSzVyPUCuNVgzOyEQvF2= Mlj1V2FPT0WU
EW-16 M1fBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm3VFRKSzVyPUCuNVg4PzdizszN M{\U[HNCVkeHUh?=
EW-7 NV3WcI5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfz[5FnUUN3ME2wMlE5QDhzIN88US=> NUPsXGVMW0GQR1XS
NCI-H727 M{PDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojuTWM2OD1yLkG5O|k1KM7:TR?= Mn7UV2FPT0WU
LCLC-97TM1 NYiwe21mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7IeG5KSzVyPUCuNlA6PTVizszN NE\TXVFUSU6JRWK=
NCI-H650 M2LYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPCZXNUUUN3ME2wMlIyOzh2IN88US=> NEf4VnhUSU6JRWK=
NCI-H2122 M3zlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMkOyPVkh|ryP M37aNHNCVkeHUh?=
SK-N-DZ NHrGRVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1roZmlEPTB;MD6yN|Y6QCEQvF2= MXnTRW5ITVJ?
HT-29 NVvCVoJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfGTWM2OD1yLkK0NlQ5KM7:TR?= Mo[0V2FPT0WU
LB771-HNC M33rfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;WZYVKUUN3ME2wMlI2QTF3IN88US=> M3fUUXNCVkeHUh?=
HT-144 NFLRenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HJN2lEPTB;MD6yOlE6OSEQvF2= MmD4V2FPT0WU
LAN-6 MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jxU2lEPTB;MD6yOlM1QCEQvF2= Mlz6V2FPT0WU
EW-18 M1q3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFyzNGZKSzVyPUCuNlcxODFizszN MU\TRW5ITVJ?
LS-1034 Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjsUFVKSzVyPUCuNlcyOzJizszN NE\4THBUSU6JRWK=
EW-11 M13Hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\4[|ZPUUN3ME2wMlI5PDN{IN88US=> Ml6xV2FPT0WU
SNU-C1 M{D1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3naW2lEPTB;MD6yPVMyOyEQvF2= MV7TRW5ITVJ?
RS4-11 M3jTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;5c45oUUN3ME2wMlM{PzV6IN88US=> NG\KXIlUSU6JRWK=
ES4 M3:5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPvTWM2OD1yLkSxNFM5KM7:TR?= NGfWTWdUSU6JRWK=
COLO-320-HSR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fJPGlEPTB;MD60NVM3QCEQvF2= NEjscmJUSU6JRWK=
NB10 M4jVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwNEW0N|ch|ryP NUjySlNRW0GQR1XS
BFTC-905 MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;ZfmlEPTB;MD60Olc2QCEQvF2= MWDTRW5ITVJ?
A375 M3j4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwNEe2NVch|ryP M4HVe3NCVkeHUh?=
SJRH30 NFHWbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7kbGtKSzVyPUCuOVA5OjJizszN NWO2OodzW0GQR1XS
NOS-1 MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwNUKyOlch|ryP Ml\wV2FPT0WU
SIG-M5 M3q3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvKPGVKSzVyPUCuOVM2PTdizszN NHHQOodUSU6JRWK=
DOK NXPjOoU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\sZZVKSzVyPUCuOVU3KM7:TR?= MlXwV2FPT0WU
NB69 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\1d4FKSzVyPUCuOVgzPTdizszN MVjTRW5ITVJ?
SK-NEP-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP0ZlNKSzVyPUCuOlAzOzZizszN MXLTRW5ITVJ?
SK-MM-2 NXvOSoJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwNkW0PVEh|ryP NUiwV|JHW0GQR1XS
NCI-H358 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwNkewPFIh|ryP NX7ldoI4W0GQR1XS
RH-1 NYXUTI02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwN{S4OVkh|ryP M4W2eHNCVkeHUh?=
NH-12 NHnRWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M334[GlEPTB;MD63OlA1PiEQvF2= M{DWWnNCVkeHUh?=
TE-12 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzLO3BKSzVyPUCuO|Y1QDZizszN MYrTRW5ITVJ?
COLO-668 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonyTWM2OD1yLki0OlY3KM7:TR?= MnXtV2FPT0WU
PANC-08-13 Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDKXWVVUUN3ME2wMlg3Ozd5IN88US=> NIW1T3RUSU6JRWK=
HCC2998 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj5TWM2OD1yLki4NlY{KM7:TR?= MX3TRW5ITVJ?
ABC-1 NVjQdGZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPEOm5KSzVyPUCuPVA{PTJizszN NYPJTYVbW0GQR1XS
ES6 NXTVOIc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwOUGwOlYh|ryP Ml35V2FPT0WU
SNU-387 M3q0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfTRVhKSzVyPUCuPVk{QTNizszN NGD5VWFUSU6JRWK=
CMK MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H0fmlEPTB;MD65PVkzQSEQvF2= M1fSU3NCVkeHUh?=
SJSA-1 NYnTRoVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojMTWM2OD1zLkCzOlU{KM7:TR?= NVjaWo9TW0GQR1XS
SIMA NYO5N4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz5TWM2OD1zLkC2PFI2KM7:TR?= MYHTRW5ITVJ?
ES3 NYfZU|BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HkSmlEPTB;MT6xNlI6PyEQvF2= NYjZcpc1W0GQR1XS
IGROV-1 NHvnXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nsVWlEPTB;MT6xOVQ1PCEQvF2= MVzTRW5ITVJ?
MEL-JUSO MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfWZoxKSzVyPUGuNVU4PTlizszN NWiyfXB4W0GQR1XS
T84 M1z4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm0UFZKSzVyPUGuNlA6OTRizszN NGmxcJhUSU6JRWK=
CAL-85-1 NHLDN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzrUI15UUN3ME2xMlI{OTN6IN88US=> NWXSdnFZW0GQR1XS
RD M{LXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTvWlRKSzVyPUGuNlY1PTVizszN M4PmenNCVkeHUh?=
TE-8 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwM{G0OlIh|ryP MnrxV2FPT0WU
L-363 Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwM{SyNFgh|ryP NX;MUo9[W0GQR1XS
EKVX NYrTdmZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;zS5lKSzVyPUGuN|Q2PjhizszN M1X5NXNCVkeHUh?=
SK-MEL-3 NGH1[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXvTWM2OD1zLkS4OVU3KM7:TR?= MkjhV2FPT0WU
TGBC24TKB M2\0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnN[JRKSzVyPUGuOVAyQTNizszN NXLKZlBlW0GQR1XS
NCI-H1770 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPlfms6UUN3ME2xMlUyOTF|IN88US=> M1jxXXNCVkeHUh?=
HuH-7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NECydJVKSzVyPUGuOlAxQThizszN NGnPeGFUSU6JRWK=
HL-60 NF3q[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfYUYVCUUN3ME2xMlY3QTJ6IN88US=> MVnTRW5ITVJ?
TE-1 NFTOc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvrcVJWUUN3ME2xMlcxQTR3IN88US=> NFzifWxUSU6JRWK=
LC-2-ad Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf5TWM2OD1zLkezPFg4KM7:TR?= MmDPV2FPT0WU
LB647-SCLC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWyS|VKSzVyPUGuO|Y2QDNizszN Mn3OV2FPT0WU
NCI-H2171 M{\KcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq0NJFKSzVyPUGuO|c4OTZizszN Ml[xV2FPT0WU
SK-PN-DW NELNUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\TXGlEPTB;MT65NVI6QCEQvF2= MYfTRW5ITVJ?
MC-IXC M1zSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwOUi5PEDPxE1? M16zS3NCVkeHUh?=
LS-513 NFi4eI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnCXo1KSzVyPUKuNFU{ODVizszN M17HZXNCVkeHUh?=
EW-3 Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2noOmlEPTB;Mj6wPVg1PCEQvF2= Mm[yV2FPT0WU
OPM-2 NWXnV4pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HtO2lEPTB;Mj6xNFIh|ryP M3LKSXNCVkeHUh?=
LP-1 NFTuNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwMkW4NFch|ryP M1jQbHNCVkeHUh?=
LU-134-A MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLFXpo{UUN3ME2yMlI4PyEQvF2= NEPXWZJUSU6JRWK=
CP66-MEL MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwMkmwNVQh|ryP Mo\6V2FPT0WU
HCC1143 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwNEWzOlgh|ryP NYrQTXFSW0GQR1XS
LOXIMVI MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHSyTW9KSzVyPUKuOlAzOSEQvF2= MkDMV2FPT0WU
TE-10 Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfmbZVrUUN3ME2yMlcxQDN6IN88US=> NHjOUZNUSU6JRWK=
NCI-H1882 NHLTNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\ibmlEPTB;Mj63OVIzPyEQvF2= NWjFSIhqW0GQR1XS
CHP-126 NXTBXVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJwN{[zNVch|ryP MnHYV2FPT0WU
NCI-H1623 M{nXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDtVXZKSzVyPUKuPVIxOjRizszN NHzkVWRUSU6JRWK=
GB-1 NWDiS3lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz3UGlKSzVyPUKuPVM1ODRizszN NFjueoVUSU6JRWK=
RCC10RGB NWDvdIlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXNTWM2OD1{Lkm1NlgyKM7:TR?= MWTTRW5ITVJ?
NCI-H2141 NGrS[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJwOU[4PVYh|ryP NIH1XVdUSU6JRWK=
GI-ME-N NULwdXVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDjfWc3UUN3ME2zMlAxPTZ3IN88US=> MUTTRW5ITVJ?
NCI-H526 M{\qSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTLdXJKSzVyPUOuNFQxQDVizszN MYXTRW5ITVJ?
NCI-H747 NX3NSIRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H4TmlEPTB;Mz6wOFk6OiEQvF2= MoG0V2FPT0WU
SNU-423 NITrZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTNwMkCzNVMh|ryP M3\YeXNCVkeHUh?=
A427 MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILDb2dKSzVyPUOuNlU3QTlizszN M4XnUnNCVkeHUh?=
CAL-12T Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlqyTWM2OD1|LkSwO|E{KM7:TR?= NU\xV4RVW0GQR1XS
LU-99A NGDJ[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfzeYZKSzVyPUOuOFcyODVizszN MknYV2FPT0WU
MS-1 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHKTWM2OD1|LkWzOFI6KM7:TR?= NVX5ZWY6W0GQR1XS
SK-LU-1 NED3O3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTNwN{[yPVUh|ryP M{TPZXNCVkeHUh?=
SW837 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNwN{[zN|Mh|ryP M1nhW3NCVkeHUh?=
ES8 MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PEWWlEPTB;Mz64N|g4PyEQvF2= NUTxSWJQW0GQR1XS
MZ2-MEL M3joWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL3WlBVUUN3ME2zMlkzODh4IN88US=> NXXHfVJzW0GQR1XS
TGW NU\WTHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P3c2lEPTB;ND6wNVMyOSEQvF2= MYTTRW5ITVJ?
GP5d MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XWOGlEPTB;ND6wOVM3OiEQvF2= NFHrbnhUSU6JRWK=
BB49-HNC MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LYN2lEPTB;ND6xOVIyOyEQvF2= M13YN3NCVkeHUh?=
NB13 NFvSOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX6wcmN3UUN3ME20MlI3QDh5IN88US=> NUj5V3hjW0GQR1XS
NTERA-S-cl-D1 M4TjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojHTWM2OD12LkK4OlE2KM7:TR?= MWnTRW5ITVJ?
NCI-H1648 NUnnZlFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTRwMkm4NVkh|ryP NXXhXpJXW0GQR1XS
LCLC-103H Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3lTWM2OD12LkOyNVk2KM7:TR?= MYHTRW5ITVJ?
LS-411N M1XVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LGdmlEPTB;ND60OFg5PSEQvF2= MYTTRW5ITVJ?
NCI-H1092 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjtTWM2OD12LkS1Olg4KM7:TR?= NHTsWodUSU6JRWK=
PANC-10-05 NH34VVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWmxb3M2UUN3ME20MlY6QDRizszN MlHHV2FPT0WU
DK-MG NHe2RlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYezbHdFUUN3ME20MlgxQTN|IN88US=> M4TidnNCVkeHUh?=
OVCAR-5 NXr5Xmt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL1TG5RUUN3ME20MlgyOjJ4IN88US=> M1LseHNCVkeHUh?=
CAL-39 M37P[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\VW2lEPTB;ND64O|Y4KM7:TR?= NF;JbYhUSU6JRWK=
TE-441-T MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPrOXZKSzVyPUSuPVA2OzdizszN M3vye3NCVkeHUh?=
MOLT-16 NHrWZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHESmlFUUN3ME20Mlk2OjV|IN88US=> MoTpV2FPT0WU
MCF7 NInyclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXjTWM2OD13LkG0OVE4KM7:TR?= NVXWUoNDW0GQR1XS
CAPAN-1 MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTVwMkW3NFch|ryP M37iXnNCVkeHUh?=
PSN1 NYHm[mdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:xUGcxUUN3ME21MlI4OjN3IN88US=> MVzTRW5ITVJ?
NCI-H292 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HEVWlEPTB;NT6zNFA1PCEQvF2= Ml\iV2FPT0WU
CPC-N Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUG0SHlWUUN3ME21MlM6PDF7IN88US=> M2frUXNCVkeHUh?=
DoTc2-4510 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[yTWM2OD13LkS1N|cyKM7:TR?= M2O2TXNCVkeHUh?=
LB1047-RCC M2PNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTVwNUW5N|Mh|ryP M1rXS3NCVkeHUh?=
MHH-ES-1 NWTDXG9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTVwNUm5NFch|ryP M3rseXNCVkeHUh?=
NMC-G1 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLvTWM2OD13LkewNlI4KM7:TR?= NWe2SmVGW0GQR1XS
SW1710 NF[3TY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly3TWM2OD13Lke0O|UyKM7:TR?= NGjCXIhUSU6JRWK=
YAPC MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXwTWM2OD13Lke2NlAyKM7:TR?= NXfiem17W0GQR1XS
22RV1 M2PIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfxTWM2OD13LkiwNFE6KM7:TR?= Mm[1V2FPT0WU
COLO-679 NFLwd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHPSWpwUUN3ME21Mlg5QTR6IN88US=> NGLQXG1USU6JRWK=
TCCSUP NIPGS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTVwOUOyOVkh|ryP MYXTRW5ITVJ?
C2BBe1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFiySXZKSzVyPUWuPVM6PyEQvF2= NWTONIN2W0GQR1XS
TE-15 NH7ReY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXja[WtjUUN3ME22MlA3PjB3IN88US=> NHL2PZFUSU6JRWK=
SCLC-21H MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTZwMUC4OFMh|ryP NXXm[mJrW0GQR1XS
EoL-1-cell MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTZwMU[1OlMh|ryP MnrjV2FPT0WU
NKM-1 M4W4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;CTWM2OD14LkG2O|Eh|ryP MWXTRW5ITVJ?
NCI-H1304 M1q4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;1OWlEPTB;Nj6yO|QzQCEQvF2= MXzTRW5ITVJ?
NB6 MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHQT3BiUUN3ME22MlI6PjJ{IN88US=> MlzXV2FPT0WU
NALM-6 NITpelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGWzPZlKSzVyPU[uN|MzOyEQvF2= Mn\4V2FPT0WU
NCI-H522 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vYW2lEPTB;Nj6zN|MxPiEQvF2= MmXvV2FPT0WU
MV-4-11 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Hue2lEPTB;Nj6zO|A4QSEQvF2= M4fqWnNCVkeHUh?=
LB2241-RCC M1Ltcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:2V2lEPTB;Nj6zPFY3PyEQvF2= NUm5Z296W0GQR1XS
NCI-H1417 NUG5ZoJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf6TmRKSzVyPU[uOFA5PDdizszN MUfTRW5ITVJ?
HT-1197 MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz2WWRKSzVyPU[uOVcyOjJizszN M2HXfHNCVkeHUh?=
P30-OHK NUHNU2N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P4[GlEPTB;Nj62Nlc4KM7:TR?= MYfTRW5ITVJ?
ALL-PO M4\Oc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTBWZFKSzVyPU[uO|E6OTZizszN NV\BXoZ1W0GQR1XS
OVCAR-4 NWPlcXRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7VTWM2OD14Lke1OFA2KM7:TR?= MnP0V2FPT0WU
HCC2157 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O0SWlEPTB;Nj63O|Q4PSEQvF2= NFjh[G5USU6JRWK=
NCI-H838 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\3emh[UUN3ME22Mlk3PDlizszN NXq4SGFDW0GQR1XS
NCI-H1299 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W3WmlEPTB;Nj65O|A6KM7:TR?= NVGwNY5{W0GQR1XS
SW954 NXnN[YpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTdwMkCwOlgh|ryP MlHGV2FPT0WU
NCI-H441 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PrSmlEPTB;Nz6zOFA3PSEQvF2= NX;GdJh3W0GQR1XS
SK-MEL-2 NXvuOmx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHlbFFMUUN3ME23MlQ5Ozd|IN88US=> MkLEV2FPT0WU
KARPAS-45 NHjzRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTdwNkW5Nlkh|ryP NVnBOnVRW0GQR1XS
CAL-54 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnjTWM2OD15LkiyPVc4KM7:TR?= NW\4TVZOW0GQR1XS
KYSE-180 NIfzSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe4N49KSzVyPUeuPFg6PDFizszN Mm\xV2FPT0WU
NCI-H187 NUflN|VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTdwOUW5OFch|ryP MXfTRW5ITVJ?
RT-112 NFHFcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn6OldPUUN3ME24MlA6Pjd5IN88US=> MkC3V2FPT0WU
NCI-H1437 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O3eGlEPTB;OD6wPVc6PSEQvF2= MkLzV2FPT0WU
SNU-449 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml24TWM2OD16LkK4NlczKM7:TR?= NH;XbINUSU6JRWK=
HCC1187 MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRThwMkmzPVEh|ryP NILzNVhUSU6JRWK=
NCI-H2030 NXTmfYVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfzSYVKSzVyPUiuN|c4OTRizszN MYLTRW5ITVJ?
HuO-3N1 M3LnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXFWZdKSzVyPUiuN|c5PDRizszN MorpV2FPT0WU
COLO-792 MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\SXmZjUUN3ME24MlQyPTJ5IN88US=> NX20SHA6W0GQR1XS
MIA-PaCa-2 NXnPOXlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rPdWlEPTB;OD64OVUxQCEQvF2= M173Z3NCVkeHUh?=
SK-N-FI M4jweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7zTWM2OD17LkC0NlUh|ryP NHG2WWlUSU6JRWK=
MMAC-SF MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTlwMEm3OVEh|ryP MoTPV2FPT0WU
NCI-H28 MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED5bVBKSzVyPUmuNVA1PjlizszN NEj6SnRUSU6JRWK=
ETK-1 MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TNNmlEPTB;OT6yPVk4PCEQvF2= Ml;tV2FPT0WU
NCI-H1993 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnwbZlKSzVyPUmuOFQzPjFizszN M13tWXNCVkeHUh?=
no-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH2TWM2OD17LkS3NVIh|ryP M2PlXXNCVkeHUh?=
ChaGo-K-1 Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXGTWM2OD17LkWxOVg{KM7:TR?= M2LBZXNCVkeHUh?=
NCCIT MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTxfVU2UUN3ME25MlU{OTZ7IN88US=> MkjsV2FPT0WU
SAS MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[5bWhKSzVyPUGwMlI1QCEQvF2= M3;m[XNCVkeHUh?=
A673 Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH5R2JCUUN3ME2xNE4{PzB2IN88US=> NHfhS4JUSU6JRWK=
NCI-H1522 M3nqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXLOG1xUUN3ME2xNE4{PzB5IN88US=> NVPwdlQ4W0GQR1XS
NCI-H810 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFyLkO5NFch|ryP NUG4VlA6W0GQR1XS
IST-MES1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULYc5pMUUN3ME2xNE41PTZ2IN88US=> M1WxfXNCVkeHUh?=
GR-ST NUfLSnlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DRN2lEPTB;MUCuOVAzPCEQvF2= M1XsSXNCVkeHUh?=
SUP-T1 NGnrcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vaOmlEPTB;MUCuO|MyPyEQvF2= MmnEV2FPT0WU
NB5 NHHue41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\u[mlEPTB;MUCuPVAzOiEQvF2= NEPzXVNUSU6JRWK=
MZ1-PC MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq4XppKSzVyPUGwMlk2PzFizszN NFLVXopUSU6JRWK=
SK-CO-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zvbGlEPTB;MUCuPVk{OSEQvF2= MmDnV2FPT0WU
Capan-2 NXrrRVNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFzLkOxPVgh|ryP Mnz5V2FPT0WU
697 M{W2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXkeopUUUN3ME2xNU43PzV5IN88US=> MljJV2FPT0WU
REH M3nPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTvcWNmUUN3ME2xNU44PDVzIN88US=> NY\IWJJjW0GQR1XS
GI-1 Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fxbmlEPTB;MUGuPFYyPSEQvF2= NUSzTZg2W0GQR1XS
BB65-RCC NUXoNYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\YU5JKSzVyPUGyMlA6OTZizszN MYrTRW5ITVJ?
NCI-H1651 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPzb4hHUUN3ME2xNk4zPDd6IN88US=> NEHpO5JUSU6JRWK=
NCI-H1618 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPJVFdKSzVyPUGyMlM6PzZizszN M3zwNXNCVkeHUh?=
NCI-H2081 Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HqRWlEPTB;MUKuOlE1OSEQvF2= MmC2V2FPT0WU
GCIY M4fSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlWwTWM2OD1zMj63NlE{KM7:TR?= MWHTRW5ITVJ?
NY MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DwZ2lEPTB;MUOuNFY1OyEQvF2= MnvlV2FPT0WU
PANC-03-27 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF|LkC4NFch|ryP Mn\CV2FPT0WU
BHY NVu4O2hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljaTWM2OD1zMz6yNVIyKM7:TR?= M{XmXHNCVkeHUh?=
SK-OV-3 M17kemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17KV2lEPTB;MUOuN|c3OyEQvF2= MnH4V2FPT0WU
5637 NWT4c3d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF|Lke3OVkh|ryP MlW0V2FPT0WU
LC-1F MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXwWmlYUUN3ME2xOE4xOzV4IN88US=> M{nlW3NCVkeHUh?=
SNB75 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljtTWM2OD1zND6wN|g{KM7:TR?= NGT5T5NUSU6JRWK=
CHP-212 NHfN[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor6TWM2OD1zND6wOFY1KM7:TR?= MUHTRW5ITVJ?
HT-1376 NVXWUVJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLh[mF6UUN3ME2xOE4yOTJ4IN88US=> NFv1VVNUSU6JRWK=
MONO-MAC-6 NGKy[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne1TWM2OD1zND6xOVAzKM7:TR?= NF:yO5JUSU6JRWK=
CA46 M2nJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPsTWM2OD1zND6xPFI4KM7:TR?= M2PyTnNCVkeHUh?=
SCC-15 M4HzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrNTWM2OD1zND61OVg{KM7:TR?= MmTTV2FPT0WU
ATN-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDsTWM2OD1zND62OlI4KM7:TR?= MlrOV2FPT0WU
NCI-H2405 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3HTWM2OD1zND64NVU4KM7:TR?= NFnWelhUSU6JRWK=
NCI-H716 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF2Lki0PVMh|ryP M1jiNXNCVkeHUh?=
SW620 M33mV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\ROGIzUUN3ME2xOE46ODF2IN88US=> MoPGV2FPT0WU
NCI-H226 M3HqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXqcoNEUUN3ME2xOE46ODh3IN88US=> MYnTRW5ITVJ?
SW962 MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF2Lkm0N|Ih|ryP MVPTRW5ITVJ?
KYSE-150 NEjVZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LwdGlEPTB;MUSuPVU2KM7:TR?= MoLuV2FPT0WU
OCUB-M M4fzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;uTWM2OD1zND65PFg{KM7:TR?= NFnrU5NUSU6JRWK=
ES7 M3f6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF3LkC5PFQh|ryP Ml:wV2FPT0WU
SW1463 NXHkcm1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:zTWM2OD1zNT60NlI{KM7:TR?= MWrTRW5ITVJ?
CAKI-1 MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTQb3lmUUN3ME2xOU42OzR4IN88US=> NV\UNJRRW0GQR1XS
MKN28 M3\IWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT4TWM2OD1zNT61OFc6KM7:TR?= NGfKTWxUSU6JRWK=
SW13 Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzF[YNKSzVyPUG1MlYyQCEQvF2= NVX1WoxMW0GQR1XS
A3-KAW MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF3Lkm2PVch|ryP M1TaWXNCVkeHUh?=
LU-65 M2Xr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF3Lkm3Olgh|ryP NV3KOZlPW0GQR1XS
Calu-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfsdGtKSzVyPUG2MlA{PjhizszN Mlf4V2FPT0WU
ST486 M124b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\zcZBKSzVyPUG2MlA1OzFizszN MXzTRW5ITVJ?
BB30-HNC M{nVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qwe2lEPTB;MU[uNVI1PiEQvF2= MVHTRW5ITVJ?
EGI-1 NHrK[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF4LkS0OkDPxE1? M2TBeHNCVkeHUh?=
SH-4 NY\ieZhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF4LkS3N|Eh|ryP NVTqOmQ3W0GQR1XS
MN-60 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fCVmlEPTB;MUeuNlI6PyEQvF2= NXfGPWNQW0GQR1XS
MPP-89 NInaS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDac2RKSzVyPUG3MlI1PTlizszN MVTTRW5ITVJ?
A2780 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj6b|RKSzVyPUG3MlQyOzlizszN M1LjS3NCVkeHUh?=
Daoy M2G4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknlTWM2OD1zNz60Olk2KM7:TR?= NWDoTmMxW0GQR1XS
NCI-H2126 NUPPe2hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\zWmlEPTB;MUeuOFc4OSEQvF2= MmryV2FPT0WU
NCI-H1563 NYHJcIZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjpOXhKSzVyPUG3MlQ6OTdizszN NYnPUlMyW0GQR1XS
8-MG-BA MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPyZoNmUUN3ME2xO{43PjR6IN88US=> NFfjVpNUSU6JRWK=
786-0 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTHS3BKSzVyPUG3Mlg{PTNizszN M3HyWnNCVkeHUh?=
AM-38 M1nCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\yWJVpUUN3ME2xO{46OzB4IN88US=> NXyxS5FvW0GQR1XS
COLO-824 NIrPR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MontTWM2OD1zOD60OFM3KM7:TR?= NEHY[5ZUSU6JRWK=
SK-MEL-30 M1ziS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTMZoJ[UUN3ME2xPE42ODh{IN88US=> NXG3R49EW0GQR1XS
CESS MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37pVWlEPTB;MUiuO|YxQSEQvF2= MXrTRW5ITVJ?
BL-70 M1zpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm3[WdKSzVyPUG4MlgyPTZizszN MmOxV2FPT0WU
NCI-H2170 NGjLc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX2TWM2OD1zOD65NVc6KM7:TR?= M17UVHNCVkeHUh?=
HT-3 M17Ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW0TWM2OD1zOD65PFMh|ryP M2LCcXNCVkeHUh?=
BOKU NVnsfZprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrze21QUUN3ME2xPU4xOzhzIN88US=> MljaV2FPT0WU
HPAF-II M37yc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\MU3N3UUN3ME2xPU4{ODF3IN88US=> NHLJfItUSU6JRWK=
KGN M3TITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF7LkS3OlUh|ryP MkHjV2FPT0WU
MC-CAR NYq1dXRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSzTWM2OD1zOT62N|E{KM7:TR?= MX3TRW5ITVJ?
BHT-101 M{POUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL2WGdKSzVyPUG5Mlc4PyEQvF2= MVLTRW5ITVJ?
SW1783 NITEcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfsVYxJUUN3ME2xPU44QDB4IN88US=> NYjqdFk6W0GQR1XS
KP-N-YN NYrRe4NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\BdmlEPTB;MkCuNFI3OiEQvF2= NYC0bog2W0GQR1XS
LU-165 NFPEZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DYZWlEPTB;MkCuOVU4OSEQvF2= MnTrV2FPT0WU
GOTO MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XuN2lEPTB;MkCuOlQ2OSEQvF2= MYnTRW5ITVJ?
EFM-19 NYjadFdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJzLkC3NVYh|ryP NVHSfGVHW0GQR1XS
CTV-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPWWFVQUUN3ME2yNU4yODV2IN88US=> MlzLV2FPT0WU
HEL MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke3TWM2OD1{MT60NlE3KM7:TR?= NX\Yb2ZKW0GQR1XS
SNU-C2B M3PlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJzLkSyOkDPxE1? M2jwVnNCVkeHUh?=
ECC4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJzLkewO{DPxE1? MmDBV2FPT0WU
NEC8 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJzLkizOlgh|ryP Moi3V2FPT0WU
KMOE-2 NGPLVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\1bpJKSzVyPUKxMlg6OjFizszN M3LkWXNCVkeHUh?=
NCI-H524 NEjaUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHQVodrUUN3ME2yNk4xQDB6IN88US=> M2T4TXNCVkeHUh?=
WSU-NHL MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ{LkG1O|ch|ryP M4K1ZnNCVkeHUh?=
SF126 NWPmNGxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;DOmlEPTB;MkKuNlQ3QSEQvF2= M1z2UXNCVkeHUh?=
HOP-92 Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDhNYV7UUN3ME2yNk4{OTZ5IN88US=> NXPkeG5NW0GQR1XS
CTB-1 NGTMbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVni[4c{UUN3ME2yNk41Pjd5IN88US=> MoCwV2FPT0WU
KYSE-270 MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\3PYFKSzVyPUKyMlk{PTdizszN NVnQTVc4W0GQR1XS
SK-MEL-24 NI\WbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;ZVnpKSzVyPUKzMlE5PyEQvF2= NFjve3NUSU6JRWK=
Calu-3 NH3yfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M363WmlEPTB;MkOuNlEzQCEQvF2= MnntV2FPT0WU
GAMG Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom2TWM2OD1{Mz6yN|Y4KM7:TR?= Mn7lV2FPT0WU
SW1573 M33nWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW1cJlLUUN3ME2yN{44PDF3IN88US=> NIe1OXZUSU6JRWK=
MHH-NB-11 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjmUGQ{UUN3ME2yOE4xOTl2IN88US=> NGja[WpUSU6JRWK=
TK10 NVjX[VNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ2LkWwNVMh|ryP NGLLN5hUSU6JRWK=
LB373-MEL-D M{\JNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPDNGZMUUN3ME2yOE43ODZ2IN88US=> MUDTRW5ITVJ?
KALS-1 NY[4dYNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJ2LkezNlch|ryP MYHTRW5ITVJ?
HUTU-80 NV72VYYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP6WFdKSzVyPUK1MlgxOzJizszN MmC5V2FPT0WU
HuP-T3 NGLnfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPnO4R7UUN3ME2yOk4yPjd2IN88US=> NYnvXJBSW0GQR1XS
OE19 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJ4LkKxOVMh|ryP M3y1ZXNCVkeHUh?=
J82 M{PkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf3c|ZKSzVyPUK2MlI1PzFizszN M3vEfnNCVkeHUh?=
DU-4475 NGfL[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3mTI1pUUN3ME2yOk4{QDF7IN88US=> NVzhd2lpW0GQR1XS
DMS-53 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jVNWlEPTB;Mk[uOVE{QCEQvF2= MXfTRW5ITVJ?
COLO-741 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jLXGlEPTB;Mk[uPFM1PCEQvF2= NGLJbVBUSU6JRWK=
SW48 NHjRe4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH1[VlYUUN3ME2yOk45QDJizszN NXfCS4dXW0GQR1XS
IGR-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWniNm84UUN3ME2yOk46OzN2IN88US=> NGHpSG5USU6JRWK=
639-V MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ5LkCyOFUh|ryP NYnTTZNxW0GQR1XS
LK-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjieItHUUN3ME2yO{41OTRzIN88US=> NHTPT2tUSU6JRWK=
NCI-H2347 NVPYTY45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH5NXVKSzVyPUK3Mlk3QTlizszN NHe3RYVUSU6JRWK=
NCI-H2228 NYLhR|U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPlWm1GUUN3ME2yPE4xQTB3IN88US=> NIHtfINUSU6JRWK=
LS-123 NVPTdVBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C3e2lEPTB;MkiuNVI3OiEQvF2= MlX6V2FPT0WU
U031 M4qzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvxbFZKSzVyPUK4MlI2OiEQvF2= MY\TRW5ITVJ?
NCI-H1792 NX[xSG5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW4TWM2OD1{OD60O|IyKM7:TR?= NIn3PHlUSU6JRWK=
NCI-H2087 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnyxTWM2OD1{OD63OVUzKM7:TR?= NF\MO45USU6JRWK=
NCI-H2342 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPwPVdKSzVyPUK5MlUzODhizszN MVPTRW5ITVJ?
SW626 MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlqzTWM2OD1{OT63OVYh|ryP MoT0V2FPT0WU
LB2518-MEL NXPUdpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j4PGlEPTB;MkmuPFE2KM7:TR?= NHf0W|ZUSU6JRWK=
RXF393 M{n2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTNyLkC5OVIh|ryP NFPjU45USU6JRWK=
LC4-1 NXexdpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;zOlNKSzVyPUOwMlMxQTJizszN MYTTRW5ITVJ?
NCI-H1694 NELle5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHVfFRKSzVyPUOwMlY3OjRizszN MnXVV2FPT0WU
K5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\wWndKSzVyPUOwMlk4ODJizszN NXHjRpF[W0GQR1XS
HDLM-2 NWW0ZpNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDHTWM2OD1|MD65O|I2KM7:TR?= NEC5SWZUSU6JRWK=
BCPAP MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNzLkizO|kh|ryP MnjOV2FPT0WU
BC-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\Hc|h5UUN3ME2zNk4yPDB|IN88US=> MnvDV2FPT0WU
LB996-RCC M3i2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTN{LkKzOVgh|ryP NFPmem9USU6JRWK=
NCI-H2009 NXXqPFl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m3OGlEPTB;M{KuOFk5OSEQvF2= MWLTRW5ITVJ?
HTC-C3 NETPOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXabnpOUUN3ME2zN{44PTF7IN88US=> MWDTRW5ITVJ?
LAMA-84 M1W2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTN2LkS0NFch|ryP NFPNfG1USU6JRWK=
CCRF-CEM MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTDTWM2OD1|ND61O|E2KM7:TR?= MmTwV2FPT0WU
AN3-CA NI\pd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPOfJJKSzVyPUO1MlA2PjhizszN MVXTRW5ITVJ?
NCI-H1734 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjuV|M3UUN3ME2zOU4zPTZzIN88US=> MVPTRW5ITVJ?
Ca-Ski Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Di[mlEPTB;M{WuOFExOSEQvF2= MYHTRW5ITVJ?
U-266 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\3PZlvUUN3ME2zOU43OTF2IN88US=> M3nwcXNCVkeHUh?=
SBC-5 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTN3Lke3PFEh|ryP NX7FUWQ2W0GQR1XS
GT3TKB NHnVNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTN5LkGxOUDPxE1? MWXTRW5ITVJ?
MDA-MB-175-VII Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN5LkKyOFgh|ryP NIjtWYJUSU6JRWK=
PFSK-1 NIHkS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTN5LkK0N|Uh|ryP MYfTRW5ITVJ?
IMR-5 M3nvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTN5LkK0PFch|ryP MUjTRW5ITVJ?
Daudi M2[yOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\hS5hMUUN3ME2zO{4{PTl5IN88US=> MnnYV2FPT0WU
A498 M4DpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i2eWlEPTB;M{euO|IyQCEQvF2= NXz2bY44W0GQR1XS
SCC-4 NH2y[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofmTWM2OD1|Nz63PFQ{KM7:TR?= NFTzdY1USU6JRWK=
COLO-680N NIrlWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTN6LkK4PFUh|ryP MXvTRW5ITVJ?
SK-MES-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTzUZZ7UUN3ME2zPE4{OjF3IN88US=> M2\FbXNCVkeHUh?=
SR NUm3WVR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP3R|lvUUN3ME2zPE42PDl3IN88US=> MkPuV2FPT0WU
LNCaP-Clone-FGC NVSyW4JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN6LkW2N|ch|ryP NXjHNm9DW0GQR1XS
SK-HEP-1 MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTvTWM2OD1|OD63PFIzKM7:TR?= MnL0V2FPT0WU
BPH-1 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\PVGlEPTB;M{iuPFMzQSEQvF2= MonJV2FPT0WU
NCI-H1755 NYK3dnhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET6U3RKSzVyPUO5MlU5OTdizszN MU\TRW5ITVJ?
LXF-289 M4rqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO2[JVKSzVyPUO5MlgxQDRizszN M33V[nNCVkeHUh?=
SW1088 NHKycndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TyXmlEPTB;NECuNlExPyEQvF2= NILrTZJUSU6JRWK=
MOLT-4 NF;LRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXCTWM2OD12MD6yPVAyKM7:TR?= Ml7sV2FPT0WU
AsPC-1 NHnJepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL2N|ZyUUN3ME20NE41PTh|IN88US=> Mm[0V2FPT0WU
HOP-62 NFXvcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTRyLk[1Olgh|ryP NHPaVFBUSU6JRWK=
A172 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[3TWM2OD12MD64OVEyKM7:TR?= NXPiPJR3W0GQR1XS
SN12C NViyZlV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojVTWM2OD12MD65N|g2KM7:TR?= M{PENnNCVkeHUh?=
MDA-MB-231 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vpdGlEPTB;NECuPVg6QCEQvF2= M3T3NHNCVkeHUh?=
RPMI-2650 NHPZWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTRzLkG1PVMh|ryP MlLKV2FPT0WU
KYSE-140 M1zseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\ic4JFUUN3ME20NU45OTJ|IN88US=> NG[zUmVUSU6JRWK=
KINGS-1 NGHaWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITPcJFKSzVyPUSyMlQ3QTdizszN M3yxVXNCVkeHUh?=
HSC-3 NFrTSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLHe4tGUUN3ME20Nk43PjZzIN88US=> NEO3cpNUSU6JRWK=
PC-14 NWOwV|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DQPWlEPTB;NEOuNVg5OiEQvF2= Mnr6V2FPT0WU
COR-L105 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTR|Lk[1NFIh|ryP NGjESXlUSU6JRWK=
BE-13 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[4e3BXUUN3ME20OE4zOzdzIN88US=> NXnBbHhNW0GQR1XS
NCI-H661 NU\ydI5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTIN2hKSzVyPUS0MlI6PThizszN MUHTRW5ITVJ?
IST-MEL1 Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:0TWM2OD12ND6zOVk6KM7:TR?= NF\yZVJUSU6JRWK=
HCC1806 M1P2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT4VG1rUUN3ME20OE42QDd|IN88US=> NFvLfGJUSU6JRWK=
COLO-800 NEHoOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTR2Lki0OVMh|ryP NH\GXIpUSU6JRWK=
IST-SL2 M4n3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmOxTWM2OD12NT6xNlQ4KM7:TR?= MlPhV2FPT0WU
8305C NHzoSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDkW|JDUUN3ME20OU4{ODlizszN M3TDe3NCVkeHUh?=
UACC-62 M4LVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTR4LkK4O|Uh|ryP MXHTRW5ITVJ?
COR-L23 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHrTWM2OD12Nz6xPVkh|ryP MULTRW5ITVJ?
EFE-184 M{XoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:1bmNKSzVyPUS3MlM5QCEQvF2= MoXDV2FPT0WU
DMS-114 NGjyOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILlN4lKSzVyPUS3MlQyPDlizszN MV3TRW5ITVJ?
KYSE-520 M4\Be2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTR6LkWzNVUh|ryP NH7OOWFUSU6JRWK=
SNG-M NGDPfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS5d|hSUUN3ME20PU41OzRizszN NEnLfmVUSU6JRWK=
A2058 M1fLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\rc4VmUUN3ME20PU41QDh3IN88US=> NGjl[21USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG 400+0.5% Tween 80+5% Propylene glycol
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID